Patvis APA

PATVIS APA is designed for real-time visualization, monitoring and diagnostics of process development, scale-up, transfer and production. There are three levels of PATVIS APA operation and you choose the level of leveraging the acquired visual information of the process, delivering the benefits of quality by design.

Mounted directly on process equipment, PATVIS APA provides a live view of the product. A high-speed camera with a telecentric optical system assures noninvasive acquisiton of detailed images for clear visualisation. Live view allows saving of all images of the process for later qualitative or quantitative analysis, which is especially useful for in-process product behavior observation and better process understanding.

PATVIS APA offers accurate measurements of CPP‘s with exceptional particle rate and excellent statistical strength in real-time, which is key to process optimisation. Proprietary and speed-optimised image analysis algorithms provide numerical data through an intuitive graphical user interface for immediate process feedback.

PATVIS APA offers software compliance to GAMP and FDA requirements and can be integrated with interfaces of production equipment for increased autonomy with automatic process monitoring, alarming and control.

Pellets are typically drug-loaded with API (layering) or film-coated to modify the API release kinetics, thereby achieving delayed or extended release. Characteristics of coated pellets, such as Pellet coating thickness and Pellet agglomerate fraction, are critical process parameters that determine the process performance in terms of product quality, product yield and production time.

Precise coating thickness control is rapidly gaining importance with an increasing amount of modified release formulations on the market. Drug release and drug loading are characterized by the thickness of the coat. PATVIS APA enables coating thickness estimation based on particle size increase even for thin film coatings on pellets and minitablets. The coating process can be terminated reproducibly when the desired end coating thickness is obtained.

Pellet agglomeration is an inevitable property of the coating process. Obtained agglomerates are a common cause for process down time and directly affect the final product yield and coat integrity. PATVIS APA enables early agglomeration detection with visual confirmation of agglomerates. Quantification of the amount of agglomerates in the process provides means for timely intervention. In this way, agglomeration can be tightly controlled.

Poster

In-line monitoring and analysis of fluid-bed pellet coating processes using PATVIS APA. 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.

Read now Download

White paper

Pellet coating optimisation with in-line agglomeration estimation. A collaborative study with Shin-Etsu Pharma & Food Materials Distribution.

Read now Download

Poster

In-line agglomeration estimation in fluid-bed pellet coating processes using PATVIS APA. 11th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology.

Read now Download

Oman Kadunc N, Šibanc R, Dreu R, Likar B, Tomaževič D.
In-line monitoring of pellet coating thickness growth by means of visual imaging. International Journal of Pharmaceutics. 2014 Aug 15;470(1):8–14.

https://doi.org/10.1016/j.ijpharm.2014.04.066

Mehle A, Kitak D, Podrekar G, Likar B, Tomaževič D.
In-line agglomeration degree estimation in fluidized bed pellet coating processes using visual imaging. International Journal of Pharmaceutics. 2018 Jul 30;546(1):78–85.

https://doi.org/10.1016/j.ijpharm.2018.05.024

Podrekar G, Kitak D, Mehle A, Lavrič Z, Likar B, Tomaževič D, et al.
In-Line Film Coating Thickness Estimation of Minitablets in a Fluid-Bed Coating Equipment. AAPS PharmSciTech. 2018 Nov;19(8):3440–53.

https://doi.org/10.1208/s12249-018-1186-x

Korasa K, Vrečer F.
A study on the applicability of multiple process analysers in the production of coated pellets. International Journal of Pharmaceutics. 2019 Apr 5;560:261–72.

https://doi.org/10.1016/j.ijpharm.2019.01.069